Why is Mankind Pharma falling/rising?

As of 11-Jul, Mankind Pharma Ltd's stock price is currently at 2,570.00, reflecting an increase of 26.6, or 1.05%. The stock has been on an upward trend, gaining for the last four days and achieving a total return of 6.12% during this period. It has outperformed its sector by 0.47% today and has consistently traded above its moving averages across various time frames. Additionally, the stock has shown strong performance over the past year, generating a return of 21.26%, significantly higher than the market's return of 0.52%. Positive factors contributing to this rise include high management efficiency with a return on equity (ROE) of 19.25%, a low debt-to-equity ratio, and healthy long-term growth in operating profit at an annual rate of 23.44%. However, there are concerns regarding negative results from March 25, including a significant increase in interest expenses and a decline in profit before tax, which could impact investor sentiment.
Broader market context indicates that Mankind Pharma's short-term performance has been notably strong compared to the benchmark, with a 5.39% return over the past week, while the Sensex has declined by 1.12%. This contrast highlights the stock's resilience in a challenging market environment. The rising investor participation, evidenced by a 60% increase in delivery volume, suggests growing confidence among investors, particularly institutional ones who hold 24.4% of the stock. Despite the positive momentum, the stock's high valuation relative to its peers, indicated by a price-to-book ratio of 10 and a PEG ratio of 53.3, raises caution about its long-term sustainability.